Emerging therapies for the management of multiple sclerosis

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 307-319

  Namaka, Michael ^a,b   Leong, Christine ^a   Prout, Michael ^a   le Dorze, Josee Anne ^a   Limerick, Mike ^b   Frost, Emma ^a   Esfahani, Farid ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Disease modifying therapy; Hormonal therapy; Monoclonal antibodies; Multiple sclerosis; Oral agent; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BUSULFAN; CARMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; ESTRIOL; ETOPOSIDE; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PROGESTERONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TERIFLUNOMIDE; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIINFLAMMATORY ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACKACHE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BUDD CHIARI SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; ESTRIOL BLOOD LEVEL; FATIGUE; GRAVES DISEASE; HEMORRHAGIC PITUITARY ADENOMA; HORMONAL THERAPY; HUMAN; HYPOPHYSIS ADENOMA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INFECTION; INTERFERON PRODUCTION; LEUKOCYTE MIGRATION; LEUKOPENIA; LIMB PAIN; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MESENCHYMAL STROMAL CELL; MONOTHERAPY; MORTALITY; MULTIPLE SCLEROSIS; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; PLEURISY; PREGNANCY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; REVIEW; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; STEM CELL MOBILIZATION; STROMA CELL; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; THYROID DISEASE; TRANSPLANTATION RELATED MORTALITY; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77952694800     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s2213     Document Type: Review

References (55)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938-52.
2. Namaka M, Pollitt-Smith M, Gupta A, et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2006;22:223-39.
3. Cui JY. Multiple sclerosis: an immunologic perspective. Phys Med Rehabil Clin N Am. 2005;16:351-8.
4. Bainbridge JL, Corboy JR, Gidal BE. Chapter 55 Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy-A Pathophysiologic Approach. 5th ed. Toronto: McGraw-Hill; 2002:1019-30.
5. Sobel RA. The pathology of multiple sclerosis. Neurol Clin. 1995;13:1-21.
6. Rodriguez M. Multiple sclerosis: basic concepts and hypothesis. Mayo Clin Proc. 1989;64:570-6.
7. Namaka M, Melanson M. Multiple sclerosis: symptomatic management. Pharmacy Practice. 2002:1-8.
8. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler. 2002;8:396-404.
9. Namaka M, St-Laurent C, Vandenbosch R, et al. Corticosteroids and multiple sclerosis: to treat or not to treat? CPJ/RPC. 2005;138:54-9.
10. Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet. 1998; 352(9139):1486-7.
11. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-31.
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 Dec; 58(6):840-6.
13. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994; 36 Suppl:S6-11.
14. Pokryszko-Dragan A, Gruszka E, Bilinska M, et al. Secondary Progressive Multiple Sclerosis-clinical course and potential predictive factors. Neurol Neurochir Pol. 2008 Jan-Feb;42(1):6-11.
15. Namaka M, Melanson M, Major J, et al. Therapeutic management of multiple sclerosis. CPJ/RPC. 2001:31-9.
16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurol. 1996;46:907-11.
17. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normalappearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol. 2005;62:569-73.
18. Namaka M, Gramlich C, Ruhlen D, et al. A Treatment Algorithm for Neuropathic Pain. Clin Ther. 2004;26(7):951-79.
19. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-6.
20. Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177(1):57-68.
21. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol. 1995;58(1):1-10.
22. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumomr necrosis factor receptor in multiple sclerosis: correlation with magenetic resonance imaging. Ann Neurol. 1995;38(2):186-93.
23. Neuhaus O, Kieseier BC, et al. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics. 2007;4(4):654-60.
24. Sipe JC. Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurotherapeutics. 2005;5(6):721-7.
25. Costello K, Sipe JC. Cladribine tablets' potential in multiple sclerosis treatment. J Neuroscience Nursing. 2008;40(5):275-80.
26. Leist TP. The potential role for cladribinee in the treatment of multiple sclerosis: clinical experience and development off an oral tablet formulation. Curr Med Res Opin. 2007;23(11):2667-76.
27. Beutler E, Koziol JA. The cladribine trial in secondary progressive multiple sclerosis: A reanalysis. Neuroepidemiology. 2000;19(2):109-12.
28. Romine JS, Sipe JC, Koziol J, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111(1):35-44.
29. Comi G. Emerging oral disease-modifying therapies for multiple sclerosis: An expert interview with Giancarlo Comi, MD. Medscape Neurology and Neurosurgery: Expert Review. May 22, 2009. Available: http://cme.medscape.com/viewarticle/702867. Accessed August 8, 2009.
30. Hartung HP, Aktas O, Kieseier B, et al. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol. 2009 Nov 18: Epub ahead of print.
31. Beutler E, Koziol JA, McMillan R, et al. Marrow suppression produced by repeated doses of cladribine. Acta Haematol. 1994;91(1):10-5.
32. de Wolf C, Jansen R, Yamaguchi H, et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Therap. 2008 Sept;7(9):3092-102.
33. Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci. 2009;30 Suppl 2(2):S179-83.
34. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs. 2009;18(7):985-9.
35. Warnke C, Meyer Zu Horste G, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333-40.
36. Coles AJ. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98.
37. Rose JW, Burns JB, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69(8):785-9.
38. Bar-Or A, Calabresi BA, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395-400.
39. Crowe JS, Hall VS, Smith MA, et al. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol. 1992;87(1):105-10.
40. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12(6):574-81.
41. Rommer PS, Stuve O, Goertsches R, et al. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol. 2008;255 Suppl 6:28-35.
42. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786.
43. Rommer PS, Stuve O, et al. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol. 2008;255 Suppl 6:28-35.
44. Soldan SS, Alvarez Retuerto AI, et al. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003;171(11):6267-74.
45. Khan O. Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology. 2007 May 29;68(22 Suppl 3):S64-71; discussion S91-6. 44.
46. Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurol. 2009;66(7):821-8.
47. Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci. 2009;17:17.
48. Sicotte NL, Liva SM, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52(4):421-8.
49. Palaszynski KM, Liu H, et al. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol. 2004;149(1-2):84-9.
50. Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics. 2007;4(4):676-92.
51. Schippling S, Heesen C, et al. Stem cell transplantation in multiple sclerosis. J Neurol. 2008;255 Suppl 6:43-7.
52. Stangel M. Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype. Nat Rev Neurol. 2009;5(6):300-2.
53. Duncan ID, Goldman S, et al. Stem cell therapy in multiple sclerosis: promise and controversy. Mult Scler. 2008;14(4):541-6.
54. Burt RK, Loh Y, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8(3):244-53.
55. Autologous Stem Cell Transplantation International Multiple Sclerosis. http://www.astims.org.